{"id":526847,"date":"2021-08-11T16:09:46","date_gmt":"2021-08-11T20:09:46","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-reports-second-quarter-2021-financial-results-and-provides-business-update\/"},"modified":"2021-08-11T16:09:46","modified_gmt":"2021-08-11T20:09:46","slug":"cyclacel-pharmaceuticals-reports-second-quarter-2021-financial-results-and-provides-business-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-reports-second-quarter-2021-financial-results-and-provides-business-update\/","title":{"rendered":"Cyclacel Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update"},"content":{"rendered":"
\n

\n
\n – Announces First Patients with Solid Tumors Dosed with Oral Fadraciclib –
<\/em>
\n <\/strong>
\n
\n – Additional Phase 1\/2 Trials for Fadraciclib and CYC140 Expected to Follow –
<\/em>
\n <\/strong>
\n
\n – Cash Runway to Early 2023 –
<\/em>
\n <\/strong>
\n
\n – Conference Call Scheduled August 11, 2021 at 4:30 p.m. ET –<\/em>
\n <\/strong>\n <\/p>\n

BERKELEY HEIGHTS, N.J., Aug. 11, 2021 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today reported its financial results for the second quarter 2021. The quarter\u2019s business highlights included an update on the Company\u2019s progress with fadraciclib and CYC140, Cyclacel’s novel CDK2\/9 and PLK1 inhibitors, respectively.<\/p>\n

\u201cAfter announcing In July that the first patient had been dosed with oral fadraciclib, two additional patients with advanced solid tumors have been treated, completing enrolment of the first dose level,\u201d said Spiro Rombotis, President and Chief Executive Officer. \u201cWe are encouraged by investigator interest in our fadraciclib 065-101 solid tumor study. In earlier clinical studies fadraciclib has demonstrated single-agent activity, including durable PR. We believe that fadraciclib is a leading, transcriptionally-active CDK inhibitor with a differentiated product profile. Pipeline momentum will continue to build with the planned opening of protocol 065-102, an oral fadraciclib study in patients with hematological malignancies, and later with the initiation of two similar protocols in solid tumors and hematological malignancies for our novel PLK1 inhibitor, CYC140. The second half of 2021 is an exciting period for Cyclacel, as we expand our clinical programs and increase our visibility as an oncology leader focused on cell cycle inhibition for the treatment of cancer. We look forward to reporting further updates as data from these studies become available.\u201d<\/p>\n

\n Key Corporate Highlights<\/strong>\n <\/p>\n